Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a one-week radiation zap be just as good as three weeks for early breast cancer?

NCT ID NCT05318274

Disease control Sponsor: Coordinación de Investigación en Salud, Mexico Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a 1-week radiation schedule to the standard 3.1-week schedule for people with early-stage breast cancer who have had lumpectomy. The goal is to see if the shorter course controls cancer just as well while causing fewer side effects. About 72 adults with ductal carcinoma in situ or early invasive breast cancer are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed by histopathological report of ductal carcinoma in situ (DCIS) or invasive breast carcinoma. * Treated with breast-conserving surgery and stage pT1-2 pN0 M0. * Over 18 years. * Patients who sign informed consent for research study. Exclusion Criteria: * Positive nodes. * Clinical or pathological stage T3-T4. * History of previous irradiation. * Postoperative positive margin.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ductal breast carcinoma in situ are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma in situ breast neoplasm ductal breast carcinoma in situ invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ductal breast carcinoma in situ Early-stage breast cancer Invasive breast cancer Stage 0 breast cancer Stage I breast cancer Stage IA breast cancer Stage IB breast cancer

Contacts and locations

Locations

  • Unidad Medica de Alta Especialidad

    Mérida, Yucatán, 97150, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.